# Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

> **NCT03663712** · PHASE1 · COMPLETED · sponsor: **Dan Blazer III, M.D.** · enrollment: 28 (actual)

## Conditions studied

- Peritoneal Surface Malignancy

## Interventions

- **BIOLOGICAL:** Talimogene Laherparepvec

## Key facts

- **NCT ID:** NCT03663712
- **Lead sponsor:** Dan Blazer III, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-23
- **Primary completion:** 2022-10-13
- **Final completion:** 2022-10-13
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03663712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03663712, "Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03663712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*